Imaging the mechanisms of anti-CD20 therapy in vivo uncovers
CL Grandjean, Z Garcia, F Lemaître, B Bréart… - bioRxiv, 2020 - biorxiv.org
Anti-CD20 monoclonal antibody (mAb) represents an effective strategy for the treatment of B
cell malignancies that may involve complement activity, antibody dependent cellular …
cell malignancies that may involve complement activity, antibody dependent cellular …
[PDF][PDF] Imaging the mechanisms of anti-CD20 therapy in vivo uncovers
CL Grandjean, Z Garcia, F Lemaître, B Bréart… - scholar.archive.org
Monoclonal antobodies (mAb) targeting tumor surface antigen represent a powerful strategy
for the treatment of several types of cancer. Rituximab, a chimeric IgG1 mAb directed against …
for the treatment of several types of cancer. Rituximab, a chimeric IgG1 mAb directed against …
[PDF][PDF] Imaging the mechanisms of anti-CD20 therapy in vivo uncovers
CL Grandjean, Z Garcia, F Lemaître, B Bréart… - researchgate.net
Monoclonal antobodies (mAb) targeting tumor surface antigen represent a powerful strategy
for the treatment of several types of cancer. Rituximab, a chimeric IgG1 mAb directed against …
for the treatment of several types of cancer. Rituximab, a chimeric IgG1 mAb directed against …
Imaging the mechanisms of anti-CD20 therapy in vivo uncovers
CL Grandjean, Z Garcia, F Lemaître, B Bréart… - 2020 - europepmc.org
Anti-CD20 monoclonal antibody (mAb) represents an effective strategy for the treatment of B
cell malignancies that may involve complement activity, antibody dependent cellular …
cell malignancies that may involve complement activity, antibody dependent cellular …